Best GLP-1 for Weight Loss in 2026: Honest Head-to-Head

There is no single "best GLP-1 for weight loss" — there's only the best for you, given your goals, what your insurance covers and what your prescriber thinks is safe. But the clinical trial data does give a clean ranking on average weight loss, and that's where most people want to start.

Here's the head-to-head, with the trade-offs that the marketing pages gloss over.

The honest ranking, by trial weight loss

| Drug (brand) | Active ingredient | Average weight loss in pivotal trial | Trial length | FDA-approved for | | --- | --- | --- | --- | --- | | Zepbound | Tirzepatide 15 mg | ~21% body weight (SURMOUNT-1) | 72 weeks | Chronic weight management; OSA | | Mounjaro | Tirzepatide 15 mg | ~21% body weight (off-label) | 72 weeks | Type 2 diabetes | | Wegovy | Semaglutide 2.4 mg | ~15% body weight (STEP-1) | 68 weeks | Chronic weight management; CV risk reduction; MASH | | Ozempic | Semaglutide 2.0 mg | ~12–15% body weight (off-label) | 68 weeks | Type 2 diabetes | | Saxenda | Liraglutide 3.0 mg | ~8% body weight | 56 weeks | Chronic weight management |

These numbers are averages from the pivotal weight-management trials. Individual results vary substantially. Retatrutide, the next generation "triple agonist", has reported even higher numbers in Phase 2 but is not yet approved — see our Retatrutide guide for what its trials show.

How each one works

Semaglutide (Wegovy / Ozempic / Rybelsus) mimics the GLP-1 incretin hormone. It binds to GLP-1 receptors, slows gastric emptying, increases satiety and improves insulin response. Single-receptor agonist. Weekly injection (Wegovy and Ozempic) or daily oral (Rybelsus).

Tirzepatide (Zepbound / Mounjaro) is a dual agonist — it activates both GLP-1 and GIP receptors. Adding the GIP arm appears to amplify the appetite and metabolic effects, which is why tirzepatide outperforms semaglutide on average weight loss in trials. Weekly injection.

Liraglutide (Saxenda) is the earlier-generation GLP-1, daily injection. Same mechanism as semaglutide but shorter half-life and generally less weight loss.

For deeper mechanism, see GLP-1 receptor agonists.

When each one is the right answer

Zepbound (tirzepatide)

Best for: Highest average weight loss in trials. Newly approved for obstructive sleep apnea in adults with obesity, which broadens the clinical indications. Dose escalation runs 2.5 → 15 mg weekly.

Watch outs: Most likely to cause GI side effects (nausea, vomiting, diarrhea) — they're typically transient but can be intense during dose escalation. Manufacturer copay programs are favorable for commercially insured patients; cash pay is reduced via LillyDirect vials.

Wegovy (semaglutide)

Best for: The strongest cardiovascular evidence in the class — the SELECT trial showed a 20% reduction in major adverse cardiovascular events. Also approved for MASH (metabolic-associated steatohepatitis) fibrosis. Often the right pick if cardiovascular risk reduction matters on top of weight loss.

Watch outs: Lower average weight loss than Zepbound (~15% vs ~21%). Same GI side-effect profile as Ozempic. Insurance coverage for weight- loss use is variable but improving.

Mounjaro (tirzepatide)

Best for: People with type 2 diabetes. Same molecule as Zepbound but labeled for glycemic control. Patients with T2D usually have far better insurance coverage for Mounjaro than for Zepbound.

Watch outs: Off-label use for weight loss without T2D is common but insurance-unsupported. Side-effect profile identical to Zepbound.

Ozempic (semaglutide)

Best for: People with type 2 diabetes who want a weekly injection. The original blockbuster.

Watch outs: Off-label use for weight loss is the most expensive brand-name path on cash pay because manufacturer savings cards are typically tied to the FDA-approved use. If your goal is purely weight loss, Wegovy is the cost-friendlier match.

Saxenda (liraglutide)

Best for: Daily-injection comfort, longer track record (approved 2014), and a useful option when supply of newer agents is constrained.

Watch outs: Lower average weight loss than the weekly options. Daily dosing is an adherence burden some patients dislike.

Side-effect profile, head to head

All GLP-1s share the same dominant side-effect pattern — gastrointestinal, dose-related, mostly transient:

| Side effect | Common | Less common | When it usually occurs | | --- | --- | --- | --- | | Nausea | All | – | First 4–8 weeks; during dose escalation | | Vomiting | All | – | Same | | Diarrhea / constipation | All | – | Variable | | Reflux / belching | All | – | Throughout | | Injection-site reactions | All | – | First few injections | | Pancreatitis | – | Rare | Any time; medical emergency | | Gallbladder issues | – | Documented | Often during rapid weight loss | | Thyroid C-cell tumors | – | Rodent signal; contraindicated in MEN-2 / MTC history | – | | "Ozempic face" | – | Visible volume loss with rapid weight loss | After substantial weight loss | | Muscle loss | – | Real concern with rapid weight loss | Over treatment course |

For a deeper safety breakdown, see GLP-1 side effects.

Who probably shouldn't take any GLP-1

• Personal or family history of medullary thyroid carcinoma or MEN syndrome type 2
• History of pancreatitis
• Severe gastroparesis already
• Pregnancy or planning pregnancy in the near term (washout periods apply)
• Active eating disorder
• Type 1 diabetes (different physiology; not a GLP-1 indication)

Decision summary

• Want maximum average weight loss? Zepbound (tirzepatide).
• Want the strongest cardiovascular protection? Wegovy (semaglutide).
• Have type 2 diabetes? Mounjaro or Ozempic, whichever your insurance covers better.
• Want a longer-track-record option / daily injection? Saxenda.
• Want maximum potential efficacy and are willing to wait? The next generation (retatrutide) isn't approved yet — but the Phase 2 numbers are eye-catching.

FAQ

Which GLP-1 produces the most weight loss? By trial average, tirzepatide (Zepbound / Mounjaro) at the 15 mg dose produces the most — about 21% body weight reduction over 72 weeks.

Is Zepbound really better than Wegovy? On average weight loss in trials, yes. On cardiovascular outcomes, Wegovy has the better evidence so far.

Can I switch GLP-1s mid-course? Yes, prescribers commonly switch patients for insurance, supply or side- effect reasons. Dose conversion is non-trivial — it has to be managed by the prescriber.

Is there a "best GLP-1 for women"? No clinically meaningful sex-specific difference among the approved drugs. Trial efficacy and safety apply across sexes.

What's the best GLP-1 if I have diabetes and want to lose weight? Mounjaro for tirzepatide users, Ozempic for semaglutide users — both treat T2D and produce weight loss, but the cost and coverage equation strongly favors whichever is on your formulary.

---

This article is for educational purposes only and is not medical advice. Discuss any medication change with a qualified healthcare professional. Articles may contain affiliate links — we may earn a commission at no extra cost to you.